^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    2d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, BrightPath Biotherapeutics Co., Ltd.
    New P1 trial
    4d
    CAR-T Cells Targeting Autoimmune Diseases (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 --> Dec 2030 | Trial primary completion date: Jul 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    4d
    CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=419, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2029 --> Mar 2027
    Trial completion date • IO biomarker
    |
    lenalidomide • bortezomib • cyclophosphamide • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel)
    5d
    KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=386, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Abecma (idecabtagene vicleucel)
    11d
    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, The First Affiliated Hospital of Soochow University
    New P1 trial
    15d
    RN1201 Injection in the Treatment of Antibody-Mediated Diseases (clinicaltrials.gov)
    P1, N=9, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting
    Enrollment open
    16d
    CADMIUM: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma (clinicaltrials.gov)
    P2, N=78, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Abecma (idecabtagene vicleucel) • iberdomide (CC-220)
    16d
    Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma. (PubMed, Blood)
    Finally, validating functional relevance, pharmacologic inhibition of NF-κB abrogated CAR-T cytotoxicity and cytokine production in vitro. Our results support that NFKB in the ide-cel product marks a signaling axis impacting CAR-T function and NFKB activity represents a global marker of T cell fitness present prior to CAR-T manufacture.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    Abecma (idecabtagene vicleucel)
    16d
    A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study. (PubMed, Blood)
    These results suggest that CAR-NKG2A technology may overcome HvGR, especially in patients with elevated NKG2A expression on NK cells. Further studies of CT0590 in RRMM and pPCL are warranted.
    P1 data • Preclinical • Journal • IO biomarker • First-in-human
    |
    KLRC1 (Killer Cell Lectin Like Receptor C1)
    17d
    Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype. (PubMed, Cancer Immunol Res)
    Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM...Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-γ signaling, and PD-L1 expression. These findings suggest T cell-redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory MM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    PD-L1 expression
    |
    Elrexfio (elranatamab-bcmm) • SAR442257 • Abecma (idecabtagene vicleucel)
    17d
    EMN2868284528MMY3005: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (2023-507632-20-00)
    P2/3, N=440, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • Carvykti (ciltacabtagene autoleucel)
    17d
    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (clinicaltrials.gov)
    P1, N=52, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ®
    |
    Carvykti (ciltacabtagene autoleucel) • Hyleukin-7 (efineptakin alfa)